Cogent Bio granted third FDA review for lead asset
Cogent Biosciences NASDAQ:COGT on Tuesday announced that the FDA has accepted its marketing application for its lead candidate, bezuclastinib, for a rare form of blood cancer, marking the third indication for which the tyrosine kinase inhibitor is currently under regulatory review in the U.S.The FD…